Micro Pharmaceuticals
Market Cap
₹1,283 ₹1,283 Cr.
P/E
0.00
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.45
Div Yield (%)
Div Yield (%)
0.05
Individual < 2 lac
Individual < 2 lac
13.44 %
Institutions
Institutions
1.48 %
Market cap
Market cap
1,283 Cr
No. of Shareholders
No. of Shareholders
3,059
OPM (%)
OPM (%)
3.27 %
PE
PE
-
Prom Holding
Prom Holding
67.20 %
ROCE (%)
ROCE (%)
-1.93
ROE (%)
ROE (%)
-
Sales
Sales
323 Cr
  • Bharat Parenterals
  • Lincoln Pharma
  • Jagsonpal Pharma
  • TJI Pharma - Small Cap
Last updated on 29 Sep 2026
  • Bharat Parenterals runs a regulated-market CDMO business and Varenyam, a branded sterile-injectables division focused on anaesthesia and sold to hospitals through the institutional channel.
  • Earnings come from the order-book-driven CDMO base and the Varenyam branded division. Order-book conversion makes quarterly revenue lumpy.
  • Management says it launched an anaesthesia molecule first in India, after clinical trials and drug-controller approval, in a Rs 1,500–1,800cr market with few competitors.
  • Varenyam is being scaled toward Rs 100cr within 18–24 months from Nov 2025, and toward Rs 250–300cr across 3–4 therapeutic divisions.
  • Varenyam's margin rose from 39% to 45% in H1FY26, notable because management itself calls institutional injectables structurally lower-margin than prescription products.
  • The board has approved a ~Rs139cr preferential share issue to 15 non-promoter investors for subsidiary projects. Allottees would hold 12.11% after the issue.
  • Near-term results depend on CDMO order-book conversion and on Varenyam's margin staying near 45%. Management guides 12–15% standalone revenue growth for FY26.
  • FY26 guide verdict was ~May 2026; no filing since
    settles delivery of the 12–15% order-book growth guide and the 45% Varenyam margin hold.
  • Preferential allotment vote EGM 23 Oct 2026
    shareholders approve or reject the Rs139cr issue; allotment to the 15 investors follows approval.
  • Q2FY27 print mid-Oct to mid-Nov 2026
    first FY27 numbers show whether the quarterly revenue fall recurred and how Varenyam is pacing.
  • Varenyam Rs 100cr milestone ~Nov 2026–May 2027
    the guided Rs 100cr of division revenue falls due in this window.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
880
52W Range
High
2274
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

5 Yes

Positive for this company

3 Neutral

Neutral for this company

8 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Order Book (Crs)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Customers

    • Alembic Pharmaceuticals Ltd.
    • Sun Pharmaceutical Industries Ltd.

    FAQs on Bharat Parenterals Ltd. Business

    Bharat Parenterals Limited specializes in manufacturing pharmaceutical formulations for domestic and international markets, aiming to become a leading company by providing high-quality products meeting customer and regulatory standards.

    Bharat Parenterals major competitors are Lincoln Pharma, Anuh Pharma, Jagsonpal Pharma, Kilitch Drugs(India), Zim Laboratories, Wanbury, Shivalik Rasayan.
    Market Cap of Bharat Parenterals is ₹1,184 Crs.
    While the median market cap of its peers are ₹755 Crs.

    Bharat Parenterals seems to be less financially stable compared to its competitors.
    Altman Z score of Bharat Parenterals is 3.75 and is ranked 5 out of its 8 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Jan May Jul Nov Jun Sep Dec
    Investor Presentation Jan May Aug Jul Nov Mar Dec
    Conference Call May Mar Nov
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material